Loading
Diabetes and Associated Disorders · Journal article
Frontiers in Microbiology · September 3, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes current knowledge on bidirectional interactions between gut microbiota and adaptive immunity in T2DM progression and complications. It provides a mechanistic framework and summarizes emerging microbiota-targeted therapeutic strategies (dietary, probiotics, prebiotics, synbiotics, postbiotics, FMT, engineered bacteria, phage therapy), noting that dietary interventions and certain supplements have preliminary clinical support, while FMT and engineered approaches remain investigational, with significant barriers to clinical translation including heterogeneity, standardization, long-term safety, and causal evidence gaps.
Narrative review. Patients with or at risk for type 2 diabetes mellitus; not a primary study with defined enrollment..
Gut microbiota dysbiosis, chronic low-grade inflammation, and disruption of immunometabolic homeostasis contribute to T2DM development and progression Microbial-derived signals modulate antigen presentation, T-cell differentiation, B-cell function, and IgA-mediated mucosal immunity, influencing Th1, Th17, CD8+ T, and regulatory T cell populations Adaptive immune system reciprocally reshapes microbial composition by regulating intestinal barrier integrity and mucosal immune homeostasis
Long-term safety, standardization failures, and interindividual heterogeneity identified as barriers but not quantified
This review does not report primary efficacy data and should be read as a knowledge synthesis and conceptual framework rather than a basis for immediate clinical action. Clinicians should understand the bidirectional microbiota–immune axis in T2DM and recognize that most microbiota-targeted therapies beyond dietary modification remain investigational, with significant barriers to standardization and long-term safety evidence.
This is a systematic review synthesizing mechanistic knowledge and therapeutic evidence to provide a conceptual framework for understanding microbiota–immune interactions in T2DM and guiding future research and clinical translation strategies.
As stated by the source record.
This review does not report primary efficacy data and should be read as a knowledge synthesis and conceptual framework rather than a basis for immediate clinical action. Clinicians should understand the bidirectional microbiota–immune axis in T2DM and recognize that most microbiota-targeted therapies beyond dietary modification remain investigational, with significant barriers to standardization and long-term safety evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder whose development and progression are influenced not only by genetic susceptibility, obesity, and lifestyle-related factors but also by gut microbiota dysbiosis, chronic low-grade inflammation, and disruption of immunometabolic homeostasis. The gut microbiota regulates adaptive immune responses through diverse signals, including microbial structural components, metabolites, extracellular vesicles, and other secreted molecules. These microbial-derived signals modulate antigen presentation, T-cell differentiation, B-cell function, and IgA-mediated mucosal immunity, thereby influencing adaptive immune populations such as Th1 cells, Th17 cells, CD8 + T cells, and regulatory T cells (Tregs). Conversely, the adaptive immune system can reshape microbial composition and functional outputs by regulating intestinal barrier integrity, mucosal immune homeostasis, and ecological niche stability, forming a dynamic and bidirectional gut microbiota–adaptive immunity interaction network. This reciprocal interaction persists throughout the progression from metabolic risk accumulation and insulin resistance to T2DM onset and diabetic complications, contributing to chronic low-grade inflammation, impaired insulin signaling, and pancreatic β-cell dysfunction. Unlike previous reviews that have primarily focused on gut microbiota dysbiosis, microbial metabolites, or innate immune regulation, this review highlights the bidirectional interactions between the gut microbiota and adaptive immunity as a central framework. We systematically summarize the underlying molecular mechanisms, dynamic disease evolution, and advances in microbiota-targeted therapeutic strategies. In recent years, dietary modulation, probiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, and engineered microbiome-based therapies have emerged as potential approaches targeting the microbiota–immune axis. Among these strategies, dietary interventions and certain microbiota-based supplements have obtained preliminary clinical support, whereas fecal microbiota transplantation, engineered bacteria, and phage-based therapies remain under active investigation. However, clinical translation of microbiome-targeted therapies is still challenged by interindividual microbiota heterogeneity, insufficient standardization of interventions, uncertain long-term safety, and limited causal evidence. Future efforts should integrate microbial composition, functional metabolic profiles, adaptive immune signatures, and host metabolic states to achieve precise patient stratification and facilitate the development of personalized microbiome-based interventions. This review provides a conceptual framework for understanding immunometabolic mechanisms in T2DM and offers new perspectives for precision therapeutic strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.